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INTRODUCTION. 
 
Lymphogranuloma venereum (LGV) is a sexual transmitted infection due to Clamydia 
trachomatis biovar L, endemic in part of Africa, Asia, South America and the Caribbean, 
but rare in industrialized countries up to 10 years ago. In 2003, a cluster of cases of LGV 
among men who have sex with men (MSM) was reported in Rotterdam. Since then, several 
reports of LGV have been reported in the largest cities in Europe, the United States and 
Australia. They have usually occurred with an anorectal syndrome. 
The purpose of this study is to summarize the expertise provided by the international 
literature about the new LGV outbreaks and to offer the first data collected on the presence 
of this disease in the Bologna area. In fact, we examine  5 cases of LGV proctitis diagnosed 
and treated at the Clinic of Sexually Transmitted Disease (STD) of the Dermatology Section 
at Sant’Orsola-Malpighi Hospital, Bologna. Particular attention will be paid to the 
laboratory method that allows identification and typing of the microorganism C. trachomatis 
serovar L1, L2, L3, leading to an etiologic diagnosis of certainty. The diagnosed cases of 
LGV will be described and compared with the international literature, trying to assess the 
risk factors, the most effective diagnostic and therapeutic procedure and the best approach 
to the patient. 
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CHLAMYDIA. 
 
Classification. 
Chlamydia are gram negative, not moving, round or oval bacteria; they are obligate 
intracellular parasites of eukaryotic cells. According to the classical taxonomy, they belong 
to the family Chlamydiaceae [1] that is comprised of the genus Chlamydia and four species, 
different from one another for phenotype, morphology and genetics: C. trachomatis, C. 
psittaci, C.pecorum and C.pneumoniae [2] (Figure 1). 
 
Order Chlamydiales 
Family Chlamydiaceae 
Genus Chlamydia 
Species C. psittaci 
C. trachomatis 
             biovar LGV (L1-L3 serotypes) 
             biovar Trachoma (ABC, D-K serotypes) 
             biovar murine ( MoPn agent) 
 
C. pneumoniae 
C. pecorum 
 
                   Figure 1. Classical taxonomy of Chlamydia. 
 
In 1999, Everett proposed a new classification based on a recent analysis of the 16S and 23S 
ribosomal DNA and on the identification of new intracellular microorganisms with a 
replicative cycle similar to Chlamydia. In this new classification, the order Chlamydiales 
includes four different families; the family Chlamydiaceae is divided into two genuses: 
Chlamydia and Chlamydofila; genus Chlamydia includes C. trachomatis, C. muridarum and 
C. Suis [1] (Figure 2). 
Everett’s classification is still under debate [3]. 
In the C. trachomatis species, 19 serovars have been identified, divided into 2 biovars, 
trachoma and lymphogranuloma venereum (LGV). Serovars from A to K belong to biovar 
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trachoma, in which serovars A, B and C induce endemic thracoma;  serovars from D to K 
induce urogenital infections,  neonatal pneumonia and conjunctivitis. Biovar LGV includes 
serovar L1, L2, L3 [4]. 
 
 
 
Order Chlamydiales 
Family Chlamydiaceae Simkaniaceae, 
Parachlamydiacee 
Genus Chlamydia Chlamydophila  
Species Chlamydia suis 
 
 
Chlamydia muridarum 
 
 
Chlamydia trachomatis 
                    MoPn 
                    LGV 
                   Trachoma 
Chlamydophila 
pecorum 
 
Chlamydophila 
psittaci 
 
 
Chlamydophila 
pneumoniae 
              TWAR 
              Koala 
              Equino 
 
Chlamydophila 
abortus 
 
Chlamydophila 
caviae 
 
Chlamydophila 
felis 
 
 
          Figure 2. Taxonomy of Chlamydia proposed by Everett. 
 
 
Cellular structure. 
C. trachomatis is characterized by two cellular stages which alternate during the 
development cycle [5]: the elementary body (size 200-300 nm) which is incapable of 
replication  but able to survive outside the host cell, and the reticular body (that reaches the 
size of 1000 nm), capable of replication but lacking the ability to infect. The reticular body 
replicates inside the infected cell and then it undergoes a reorganization process that 
transforms it into elementary body, which protrudes from the infected cell as a result of a 
process of lysis (Figure 3). Transmission therefore occurs through the elementary body, 
whether it be a sexual transmission or from mother to foetus. 
 
 
 
 
         Figure 3. Infecting cycle of C. trachomatis. 
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Chlamydia presents a morphology similar to other gram – bacteria, but the cell wall does 
not contain any peptidoglycan ( this is the cause of its resistance to ß-lactam antibiotics) 
[6,7]. 
Lipopolysaccharide (LPS) is localized on the outer membrane; the LPS is similar to that of 
enterobacteria, but it is equipped with lower cytotoxic activity, so as not to kill the host cell. 
The outer membrane is made by the Outer Membrane Proteins (OMPs); about 60% of 
OMPs is represented by MOMP (Major Outer Membrane Protein), 38-40 kDa. MOMP 
presents genus-specific, specie-specific and type-specific antigens, targets of human 
antibodies; furthermore, it seems to play porinic function [8,9]. The other OMPs are two 
Cystein rich Proteins (CrP): the large CrP (60 kDa) and the small CrP (12 kDa). They are 
synthesized late during the replicative cycle and they are found in the membrane 
simultaneously to the appearance of the elementary bodies. This particular structure of the 
outer membrane seems responsible for preventing the fusion of fagosome with lysosome 
within the parasitized cell [10,11]. 
 
Infecting cycle. 
The infection of an eukaryotic cell starts with the adhesion of an elementary body to the 
cytoplasmatic membrane. Elementary bodies possess an adhesion molecule similar to 
heparan-sulfate glycosaminoglycans (GAG) that binds a receptor expressed on cell 
susceptible to infection. Moreover, it seems that proteins of the outer membrane of the 
elementary bodies, equipped with negative electric charge at physiological pH, can 
consistently influence the infectivity of Chlamydiae [12]. The protein MOMP seems also to 
be involved in the adhesion process: treatment of the elementary bodies with trypsin, which 
determines partial digestion of MOMP, leads to the loss of the adhesive ability of 
Chlamydiae [13]. 
The entry of elementary bodies in the host cell takes place according to what has been called 
"phagocytosis determined by the parasite”: it seems a process of endocytosis conducted by 
the eukaryotic cell on the basis of a signal generated by the contact with the elementary 
body; energy consumption by Chlamydiae is not required. The Tarp protein seems to play 
an essential role in this process: it is a species-specific protein, translocated when the 
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elementary body contact the host cell; Tarp promotes the mobilization of actin and the 
modification of the chlamydial cytoskeleton [14]. Afterwards, the elementary bodies stay 
within the cytoplasmatic inclusions where they undergo a reorganization process over a 
period of 4-5 hours; their volume increase and, after 14-18 hours, they become reticular 
bodies, characterized by a reticular homogeneous structure observable under  an electron 
microscope. The inclusions are unique vacuoles, different from the classical endocytic 
vacuoles; they do not undergo acidification or fusion with lysosomes, thanks to the ability 
of Chlamydiae of preventing the fusion of the phagosome in which they are contained with 
lysosomes. Probably, at this point, some relevant mechanisms favoring Chlamydiae survival 
are activated, as the modification of the endosomyc membranes, in order to allow the 
passage of nutrients [15,16]. Only C. trachomatis accumulates a significant amount of 
glycogen granules inside the inclusion; these granules are visible under the electronic 
microscope after staining with Lugol’s liquid [17]. Between 18 and 24 hours after infection, 
some reticular bodies undergo a process of reorganization with a progressive reduction of 
their size, which leads again to the formation of elementary bodies. Then, the vacuolar 
membrane and the cytoplasm are digested by the cellular lysosomal enzime and Chlamydiae 
are released outside through cytolysis, starting a new infecting cycle. 
About receptors on eukariotic cells, adhesiveness studies on HeLa and McCoy cells have 
shown that any serotype of C. trachomatis may be inhibited by another; this implies, at least 
for C. trachomatis, that the receptor present on eukaryotic cells is unique [18]. 
 
Metabolism, genetic and antigens. 
Chlamydiae are able to synthesize autonomously several organic substances of low 
molecular weight and can provide for macromolecular synthesis by themselves, if the 
appropriate precursors are available. On the other hand, Chlamydiae are not able to produce 
energy (ATP, adenosine tri-phosphate) and this makes them obligate intracellular parasites 
[19]. 
The first genetic map of the genome of C. trachomatis was elaborated in the early 1990s. It  
permitted  to estimate the genome of Chlamydiae in about 1.0-1.2 Mb, one of the smallest 
prokaryotic genomes which are able to encode approximately 600 proteins [20]. The 
homology of the chromosomal DNA between the three species of Chlamydiae is low and a 
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significant genetic variability was also found among some serotypes belonging to the same 
species of C. trachomatis [21].  
In addition to the genome, some extra-chromosomal elements  were identified in 1980 [22]. 
Some strains of C. psittaci and C. pecorum, almost all of the strains of C. trachomatis and 
only one equine strain (N16) of C. pneumoniae, contain a multicopy plasmid (5 to 10 
copies) of 7.5 kbp, also called “cryptic plasmid”, encoding eight ORFs (Oper Reading 
Frames) larger than 100 amino acids. The sequence of these plasmids is widely conserved 
within the different strains of C. trachomatis, although some cases have been described in 
which the same plasmid was missing without causing any functional consequence for the 
bacterium, suggesting that its presence is not essential for the survival of C. trachomatis. 
This plasmid is the target of molecular techniques for diagnosis of C. thracomatis. In fact, 
the presence within each single bacterial cell of 5-10 copies of plasmid amplifies the ability 
to detect a single bacterial cell, thereby increasing the sensitivity of these techniques [23]. 
Chlamydiae express genus-specific, species-specific and type-specific antigens. The main 
antigens are LPS, MOMP, responsible for most of the reactivity of sera in 
microimmunofluorescenze test, large CrP and a heat-shok protein of 60 kDa [24]. 
 
Pathogenetic mechanism. 
Although Chlamydiae are obligate parasites with a clear cytolytic effect in cultured cells in 
vitro, evidence of a significant toxic effect in vivo is modest. During an acute infection, the 
infected mucous ephitelium presents an intense infiltration of polymorphonuclear cells, T-
lymphocytes and B-lymphocytes, with consequent production of inflammatory cytokines. 
The immune response of the host seems to be involved in the genesis of mucosal damage 
[25]. 
The immune reaction is not able to quickly sterilize the focus of infection; prolonged 
inflammation may be able in time to suppress infection, but it may bring to a standing 
impairment of the tissues. In case of subsequent infections, the tissues impairment is often 
exacerbated by the chronic immune response and by the intense production of cytokines that 
stimulate fibrogenesis. 
The host  responses to Chlamydiae infection are different; they are responsible for 
resistance to re-infection and involved in the resolution of the disease. In the first phase of 
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the infection, the antibody response (IgG) is  serotype-specific, preferentially recognizing 
the protein MOMP. In chronic or systemic infections supported by Chlamydiae, gender-
specific antibodies against LPS and against large CrP appear. Although MOMP is the main 
antigen especially in infections with C. trachomatis and C. psittaci, sera of patients infected 
with C. pneumoniae may also recognize MOMP, possibly with a weaker reactivity [26,27]. 
 
C. trachomatis infections. 
C.thracomatis includes 15 serotypes (or serovars), recognizable through antigenic 
differences of MOMP [28]: 
- serotypes A, B, Ba, C cause endemic thracoma 
- serotypes D, E, F, G, H, I, J, K are involved in genito-urinary infection in adults and 
conjunctivitis and pneumonia in newborns 
- serotypes L1, L2, L3 cause lymphogranuloma venereum. 
In addiction to these accepted serovars, some genovariants are described, as Da, Ja, L2a, 
L2b, L2c [29]. 
Chlamydiae non-L infections will not be topic of discussion in this paper. 
 
C. trachomatis diagnosis. 
Diagnosis of C. trachomatis infection is based on laboratory techniques. Possible samples 
are urethral and cervical swabs, first void urine, semen, rectal swabs, specimen collected 
from upper genital tract (Fallopian tubes, endometrium), buboes aspirate, nasopharyngeal 
and conjunctival specimen.  
The following diagnostic techniques are available [30]. 
 
1. Direct cytological examination. This technique is useful in diagnosing acute 
conjunctivitis in newborns. It consists in a smear air dried and fixed with methanol, 
then colored with Giemsa; the diagnostic clue are intracellular basophilic and 
pinkish-blue inclusions. 
2. Isolation in cell culture. It is the only procedure that confirms the presence of viable 
organisms. Clinical specimens, diluted in a suitable transport medium, are inoculated 
in  pretreated cells (McCoy, Hep-2 and HeLa cells are most commonly used) and 
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centrifuged; after incubation for 48 to 72 hours, a cell monolayer is stained for 
intracytoplasmic inclusions with iodine staining or Giemsa or tested with fluorescent 
monoclonal antibodies binding MOMP’s epitopes. Immunofluorescence is the 
preferred method and it shows a roundish intracytoplasmic inclusion. Culture is 80-
85% sensitive and 100% specific, but time-consuming and it requires a laboratory 
equipped for cell culture. 
3. Antigen detection with immunoassays. A number of commercial EIAs (Enzime 
Immuno Assays) are available for detection of chlamydial antigens. These tests use 
monoclonal or polyclonal antibodies to detect LPS; they are fast and simple to 
perform, but sensitivity for genital infection is 60-80% compared with the culture. 
False-positive results are possible because LPS is expressed by other bacteria.   
4. Serology. Serology is not recommended for the diagnosis of chlamydial infection, 
with the exception of infection in newborns, in women with tubal infertility and 
occasionally in LGV when other tests are not available. In fact, all these more 
invasive syndromes are characterized by high levels of antibodies.  
Microimmunofluorescence (MIF) is the current method of choice. MIF is performed 
on a glass with suspension of elementary bodies of C. trachomatis, C. pneumonia and 
C. psittaci. Patients sera are tested against various antigens simultaneously and 
antibodies towards different chlamydial species are detected. 
5. Nucleic Acid Hybridization (NAH). These tests has been widely used in the nineties 
and are based on the identification of specific DNA sequences with radioactive 
probes. Sensibility and specificity are similar to EIA. 
6. Nuclei Acid Amplification (NAA). These tests seek for bacterial DNA (usually the 
target sequence of DNA is the “cryptic plasmid”, that is substantially present in most 
common serotypes of C. trachomatis) by Polymerase chain reaction (PCR) or Ligase 
Chain Reaction (LCR), with the possibility of detecting the presence of a single 
elementary body. Nowadays NAA is considered the gold standard test for diagnosis 
of genital infection because its sensitivity has surpassed that of the culture. The 
disadvantages are the need of a laboratory equipped for molecular biology, the 
possibility of false-positive results and the high cost. 
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LYMPHOGRANULOMA VENEREUM 
 
Lymphogranuloma venereum (LGV) is a venereal disease caused by C. trachomatis biovar 
L. It was described for the first time in 1833 by Wallace [31] and during the Nineteenth 
century it was considered a climatic disease, also named “tropical bubo” because it was 
more common among Africans; only in 1912 Rost identified its infective nature [32]. 
LGV is endemic in certain areas of Africa, Southeast Asia, India, the Caribbean, and South 
America. It is rare in industrialized Countries, but in the last 10 years it has been 
increasingly recognized in North America, Europe, and the United Kingdom as causing 
outbreaks of proctitis among men who have sex with men (MSM). 
 
Etiology. 
LGV is a systemic sexually transmitted disease caused by C. trachomatis serovar L1, L2, 
L3. L2 includes some variants, classified according to differences in amino acids of the gene 
omp1: L2a, L2b and the recently discovered L2c-g [33,34]. The recent spread of the disease 
in Western Countries is mainly driven by serotype L2b, identified in the first cluster of 
infection in Rotterdam in 2003 [35]. It seems that this Chlamydiae strain has been 
circulating in the Netherlands and presumably in Europe since 2000; moreover, it has been 
isolated retrospectively in rectal samples obtained from MSM in San Francisco during the 
period 1979-1985 [36]. This could suggest that L2b strain has been  present for more than 
25 years and the current LGV outbreak in industrialized Countries has most likely been a 
slowly evolving epidemic with an organism that has gone unnoticed in the community for 
many years and that is now being detected by new technologies.  
A summary of LGV reports since the cases of San Francisco till the recent European 
outbreak is represented in Figure 4 [37]. 
 
Figure 4. Published case reports of lymphogranuloma venereum in men who have sex with men 
occurring worldwide between 1981 and December 2004; cases from 2000 to 2003 were determined 
retrospectively. 
 
 
Epidemiology. 
The exact incidence of LGV is difficult to estimate; in fact, LGV is not subjected to 
mandatory reporting in most of the countries. Epidemiological surveillance is active only in 
some countries and it often considers data relating to high-risk population attending clinics 
for sexually transmitted diseases. Moreover diagnostic tests are not available in every 
laboratory and there are no screening programs. 
The European Center for Disease Control reported about 1400 cases of LGV from 1990, but 
the cases were reported only from 16 countries where techniques for genotyping of C. 
trachomatis are available. The most affected age group is the  35-44 years group , followed 
by the  25-34 years group [38]. 
Several prevalence studies in special population are available.  
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Annan et al. found 36 rectal LGV infections in 3076 MSM in London during 2009 
(prevalence 1,2%) [39]; in the same year, Ward et al. identified 61 cases in 6778 MSM 
patients attending 4 different clinics in the UK (prevalence 0,9%) [40]. 
A Dutch study on 1445 MSM patients found a prevalence of 3,1% [41]. 
In Australia, Templeton has obtained a prevalence of LGV infection of 0,3% in 2082 
symptomatic or asymptomatic MSM patients [42]. 
A Finnish study found 9 rectal positive swabs  for LGV on 1316 MSM (prevalence 0,7%) 
[43]. 
An American study has identified a prevalence of 0,87% in a group of 1671 Afro-
Americans MSM participating in the HIV Prevention Trials Network [44]. 
 
Clinical presentation. 
The classical clinical course of LGV consists of three stages [45]. During the first stage that 
usually occurs 3-30 days after inoculation, a painless papule erodes to form a small ulcer 
that heals rapidly with no scarring. The most common sites of infection are the coronal 
sulcus, prepuce, glans and scrotum in men, the posterior vaginal wall, posterior cervix or 
vulva for women; infection site may be also in rectal or pharyngeal mucosa, according to 
the kind of sexual contact. This transient ulceration, that often goes unnoticed by the patient, 
may be associated with urethritis or cervicitis. 
The secondary stage begins 2-6 weeks after the primary lesion; it consists of painful 
inguinal lymphoadenopathy, often ipsilateral, if the inoculation site was on the skin of penis, 
vulva or perineum. Inflamed lymph nodes may coalesce to form buboes, that open on the 
skin in about one third of cases. Inguinal lymphoadenopathy is not appreciable in case of 
cervical or rectal infection; in these cases pelvic nodes are involved, causing unspecific 
abdominal pain or proctitis. Constitutional symptoms associated with the second stage 
include fever, chills, myalgias, and malaise; systemic spread of infection may occur  with 
arthritis, ocular inflammatory disease, cardiac and pulmonary involvement, aseptic 
meningitis, hepatitis. 
If infection is untreated, some patients may develop the third stage of disease: it is a chronic 
granulomatous inflammation that cause lymphatic obstruction, fistula and stenosis 
development, with severe functional impairment. Possible rectal complications are 
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perirectal fistulas, abscesses and rectal stenosis. Men with urethral infection may develop 
urethral stenosis and elephantiasis of the groin. Enlargement, thickening  and fibrosis of the 
labia may occur in women, a condition termed esthiomene. 
Despite a rectal involvement may rarely be present during the secondary stage even if the 
inoculation site was elsewhere, LGV proctitis is the main clinical presentation in the recent 
diffusion of LGV in men who have sex with men (MSM). It is  characterized by anal pain, 
mucopurulent or hematic secretions, constipation or rectal tenesmus, usually occuring a few 
days after unprotected anal intercourse; inguinal lymphoadenitis is rare, since the most 
common site of infection is the rectum. A discrete ulcerative lesion may exist transiently in 
the rectal or perianal mucosa but no clear distinction is likely between ‘primary’ and 
‘secondary’ proctitis, if anorectal transmission has occurred. LGV proctitis in MSM should 
be seen as a primary manifestation of infection following direct transmission to the rectal 
mucosa [45]. LGV proctitis may associate with constitutional symptoms, like reactive 
multi-joint arthritis [46]. 
During the last years, some authors have identified some cases of oro-pharingeal LGV 
[47,48,49], but identification of C. trachomatis serovar has not been obtained. 
Although most of the recent cases of LGV present with proctitis, a small but significant 
number of inguinal-genital cases of LGV in MSM have been observed [50,51,52].  
Despite the preponderance of rectal syndromes, the recent spread of the infection is not 
confined to LGV proctitis, but the 'classic' LGV is still present [53], being able to involve 
women [54] and heterosexual couples [55].  
Finally, some cases of rectal or urethral LGV in asymptomatic patients have been identified 
[56,57]. 
 
Mode of transmission among MSM. 
In the recent outbreak of LGV, the reported cases of LVG proctitis are many more than 
those of inguinal-genital syndrome; this fact suggests that transmission can occur from 
rectum to rectum, through fisting, sexual toys or enema [58]. Moreover, diagnostic 
techniques for C. trachomatis based on PCR on urine or on urethral swabs result negative in 
some patients with inguinal syndrome; in these cases C. trachomatis is more easily found in 
ulcer swabs or bubo aspirate; this could induce underestimation of classical LGV[52]. 
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Risk behaviors for LGV proctitis are having unprotected receptive anal intercourses, using  
enemas and anal drugs, having sex  in darkrooms, at sex parties and with HIV-positive 
partners [59]. It seems that rectal douching before intercourse for hygienic reasons could 
induce loss of integrity of the rectal mucosa, facilitating the transmission of infection, as 
already shown for hepatitis B [60] and hepatitis C [61]. 
Asymptomatic infections that might serve as reservoirs are rare. In a study conducted on 
6778 rectal and 4825 urethral samples from MSM attending four genitourinary medicine 
clinics in the United Kingdom, only 4 out of  the 63 positive samples have been from 
asymptomatic patients [58]. In a French study which has been performed recently on 2012 
anorectal samples positive for C. trachomatis, 371 cases of LGV proctitis have been 
identified, 98% of which were symptomatic [62]. 
In addition, several studies trying to identify a significant reservoir of asymptomatic 
infection, urethral or rectal, in the general population, have failed [63,64], confirming that 
the infection appears to be restricted to the MSM population. 
In the last twenty years of the Twentieth Century, LGV was rare or misdiagnosed in MSM; 
some authors suggests LGV was present but not diagnosed because genotyping of C. 
trachomatis was not currently performed[65] . 
Another theory suggests that the spread of infection can be explained in the context of the 
immune reconstitution inflammatory syndrome (IRIS), characterized by paradoxical 
infections and inflammatory processes in immunocompromised HIV-infected patients, early 
after the beginning of the antiretroviral therapy. According to this hypothesis, the HIV-
positive patients with asymptomatic LGV proctitis,  would become symptomatic when their 
immune system responds to the antiretroviral therapy [66]. However, the same authors 
analyzed the association between having symptomatic LGV and the beginning of the  highly 
active antiretroviral therapy (HAART) but no association was found and this hypothesis was 
subsequently disproved [59]. 
The changes in antibiotics requirements occurred in the last 20 years could be also 
considered. In fact, until the Nineties, most of the physicians used to treat urethral and rectal 
infections by Chlamydiae and nongonococcal urethritis with doxycycline for 7-10 days. 
Doxycycline was also used to treat unspecific proctitis and  it was also given as part of 
many antigonococcal regimens to cover possible concomitant chlamydial infection. 
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Subsequently, over the past ten years, doxycycline has been gradually replaced with 
azithromycin in the treatment of chlamydial infection and nongonococcal urethritis. 
Azithromycin 1 gram in single administration has lacked to  prove its efficacy in the 
treatment of LGV and rectal non-L chlamydial infection. If a short-course doxycycline 
therapy was effective at suppressing the spread of LGV infection for decades is still to be 
confirmed [44]. 
However, atypical presentation, lack of knowledge of the disease by physicians and patients 
and lack of diagnostic routine tests for chlamydial genotyping have lead to delays in 
diagnosis and treatment, impacting on the spread of infection in  Western countries [67]. 
The current epidemic outbreak of LGV represents a significant public health problem, since 
LGV can facilitate both the transmission of HIV infection and other sexually transmitted 
disease [68]. 
 
Coinfection. 
HIV 
A strong association between LGV and HIV positivity is described by the literature:  
percentage of co-infection ranges from 67% to 100% across the reports [68]. In practice, 
two thirds of MSM with LGV are HIV-positive. The association between LGV and HIV 
may be linked to biological interactions between the two pathogens, but the microbiological 
studies that have been conducted up to now  have not identified alterations in chlamydial 
infective cycle induced by HIV co-infection [69]. HIV-infection has been reported to cause 
abnormalities in the structure and function of the intestinal epithelial barrier function as well 
as abnormal lymphocyte trafficking that may facilitate LGV acquisition [70]. On the other 
side, LGV, as other ulcerative STDs, may increase both the acquisition and transmission of 
HIV infection [71]. 
The strongest confounder about the association LGV-HIV is high-risk sexual behavior. In 
fact, there have been behavioral changes in MSM communities as a response to HIV 
epidemic, and serosorting may make HIV-positivity an intermediating factor: individuals 
participate in certain type of practices partly because of their HIV-infection. Seroadaptive 
behavior can reduce the number of new HIV infections but it also facilitates the spread of 
other STIs inside a specific network [68]. 
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HIV infection does not change clinical manifestation of LGV and does not alter the 
response to antibiotic treatment [59]. 
 
HCV 
During the last decade, outbreaks of acute hepatitis C virus (HCV) infection have been 
reported among HIV-infected MSM in several European countries. In most of the cases 
diagnosis of HCV is strictly preceded by diagnosis of an ulcerative STD, as syphilis or LGV 
[72]. 
LGV and HCV probably share several high-risk behavior, as rough sexual intercourse, 
traumatic practices and use of drugs. 
In the literature, co-infection between LGV and HCV reaches a prevalence of 19% in some 
studies [73]. 
 
Diagnosis. 
Currently, a diagnosis of certainty of LGV infection may be currently achieved only by 
detecting the biovar-specific C. trachomatis DNA with molecular biologic tests. These 
techniques may be applied on biological samples taken from the primitive anogenital 
ulceration, from the bubo aspirates, if present, or on anorectal swabs, preferably collected 
during proctoscopy, but also a blind anorectal swab can suffice. 
Biological samples first undergo a commercial C. trachomatis NAAT test identification; 
although commercially available tests are not approved for extragenital sites, a large body of 
literature supports the use of these tests for the detection of rectal chlamydial infections 
[66,74,75,76]. If the sample is positive, the biovar-specific DNA is identified with a Home-
made PCR;  at the beginning , a real-time PCR-based test that specifically detects all C. 
trachomatis LGV biovar strains was available [77] and more recently, a real-time quadriplex 
PCR-based assay which incorporates both LGV-specific and non-LGV-specific target 
sequences, a C. trachomatis plasmid target, and the human RNase P gene as an internal 
control[78].  
If biologic molecular tests are not available, a presumed diagnosis may be based on clinical 
symptoms supported by chlamydial-specific serology, especially a high titre of IgA anti-
MOMP antibodies. However, a low IgA titre does not exclude the diagnosis and high IgA 
level in asymptomatic patients does not confirm LGV infection [35,66]. 
Histopathology of mucosal manifestations is not specific; it usually shows a chronic, mainly 
lymphocytic, inflammatory infiltrate and hyperplasia of lymphatic follicles [79]. 
Microscopic examination of rectal smear test may raise the suspicion of LGV proctitis if it 
shows an increase number of  polymorphonuclear leukocytes (>10-20 cells/high power 
field); this finding does not exclude a gonococcal proctites [45]. 
A proposal to define certain, probable or possible LGV infection [80] is summarized in the 
table below (Figure 5). 
 
Criteria Classification   
 Confirmed Probable Possible 
LGV pathology or contact with LGV patient Yes Yes Yes 
C. trachomatis serology, invasive titres Positive/unknown Positive Positive 
C. trachomatis PCR (urine/rectum) Positive Positive Unknown
C. trachomatis PCR genotype serovar L1–L3 Positive Unknown Unknown
Figure 5. Lymphogranuloma venereum (LGV) case definition proposed and used in the 
Netherlands since January 2004. 
 
Differential diagnosis. 
The main differential diagnosis are other ulcerative STDs, as herpes simplex, non-LGV 
Chlamydia, gonorrhoea and syphilis, chronic bowel inflammatory diseases and rectal 
carcinoma. 
Anorectal herpes simplex usually presents with mucosal ulcerations and pain and it should 
be excluded by Tzank smear examination or by specific PCR [81]. 
Non-LGV Chlamydia proctitis is usually slightly symptomatic; diagnosis is based on 
biovar-specific DNA identification [81]. 
Gonococcal proctitis provokes mucopurulent discharge, pruritus or pain. A gram stain of 
discharge showing gram-negative diplococcus may point out the diagnosis; culture is the 
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preferred diagnostic techniques, since it also provides information about antibiotics 
susceptibility; NAAT is also a sensible and specific test [81]. 
Primary syphilis can occur with anal ulcerations with discharge and pain; a non-treponemal 
serologic test (VDRL or RPR) and a specific treponemal antigen test (FTA-ABS) must 
always be performed  in patients with suspected infective proctitis [81]. 
LGV proctitis may be in the form of inflammatory bowel disease in MSM. In fact, clinical 
endoscopic and histological findings in LGV can be indistinguishable from those of IBD, as 
Crohn’s disease or ulcerative recto-colitis. LGV proctitis may be misdiagnosed and treated 
with anti-inflammatory therapy with the risk of late complications. A rectal swabs for C. 
trachomatis NAAT is recommended in case of proctitis, especially in MSM. If C. 
trachomatis NAAT is not available, LGV proctitis should be considered in case of IBD 
treatment failure, in HIV positive or MSM patients, if Chlamydial serology is positive and 
in case of healing after treatment with doxycycline [82]. 
Rectal localization of LGV can be confused with colon-rectal cancer; in case of a rectal 
neoformation with histological examination negative for malignancy, C. trachomatis 
infection has to be ruled out [79]. 
 
Treatment. 
Despite the lack of controlled randomized studies, current guidelines recommend oral 
doxycycline 100 mg twice a day for 21 days to treat LGV; most of the reported cases  by  
the literature obtained  complete response with this treatment, also in HIV co-infection. 
Second line treatment is oral erythromycin 500 mg four times a day for 21 days. 
Azithromycin 1 gram in single or multiple doses has been proposed, but there is no evidence 
to recommend this therapy. 
Fluctuant buboes should be aspirated through healthy adjacent skin, while surgical incision 
is not recommended due to potential complication such as chronic sinus formation. 
A complete screening for STDs should be proposed in each case of LGV. 
Sexual contacts of the last 3 months should be screened for LGV and empiric antibiotic 
treatment should be started until LGV has been excluded. 
A test of cure for LGV is not necessary if treatment with doxycycline is completed [83].  
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MOLECULAR BIOLOGY. 
 
Molecular biology techniques available to point out the nucleic acids of microorganism in 
biological samples are the nucleic acid hybridization (NAH), that use probes to identify a 
specific target, and the nucleic acid amplification (NAA). NAA is the most used because of 
its greater sensibility. 
Both NAH and NAA begin with the same procedure, the extraction of nucleic acids. 
 
Extraction of nucleic acids. 
Extraction of nucleic acids (DNA or RNA) from biologic samples consists in purifying and 
concentrating the nucleic acids, removing potential inhibitors of amplification reaction. The 
kind of biological sample influences difficulty and price of the extraction process: blood, 
plasma, cerebrospinal fluid require an easier process than feces, sputum, aspirates or bones. 
Furthermore, the kind of microorganism also influences extraction: fungi and mycobacteria 
are more complicated than viruses. 
Extraction of nucleic acids is mainly based on separation methods with organic solvents, 
methods for affinity or ion exchange. Automated systems for the extraction of nucleic acids 
from clinical samples (serum, plasma, urogenital swabs, urine, cerebrospinal fluid, etc. ..) 
with standardized rapid and simple methods, have been  commercially available for a 
decade. Moreover, these automated systems are equipped with an internal control, that is 
subjected to the same treatments of the biological sample, thereby demonstrating their 
validity. The automated systems exploit the principle of affinity of the nucleic acids to the 
silica, which is located on the surface of magnetic beads (Figure 6), or the bond to 
DNA/RNA  capture probes: in the latter case specific probes for nucleic acids are bonded to 
the magnetic beads [84]. 
  
                 Figure 6. Automated extraction of nucleic acids exploiting affinity to silica. 
 
Nucleic acids amplification. 
The nucleic acid amplification techniques are PCR (Polymerase Chain Reaction), TMA 
(Transcription-Mediated Amplification), NASBA (Nucleic Acid Sequence-Based 
Amplification) and LCR (Ligase Chain Reaction). PCR is the most used both for research 
and diagnostic purposes. 
PCR, invented by Kary Mullis in 1985, is a quick, sensitive and flexible method to amplify 
in vitro predetermined sequences of DNA or RNA, generating millions of copies, from an 
initial complex source of nucleic acids. 
PCR requires two short sequences (primers) complementary to the sequences flanking the 
stretch of  DNA segment to be amplified. The enzyme DNA polymerase is able to 
synthesize a DNA strand starting from the same pair of primers (short DNA sequences that 
hybridize at two different point of the DNA sequences), using the opposite strand of DNA 
as template. In order to  use PCR for diagnostic purposes it is necessary to know a genomic 
sequence of the microorganism to be used as a target; in this way two specific primers, 
hybridizing respectively in two different points of the sequence of the target DNA, can be 
synthesized. 
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In a first step it is necessary to ensure  the separation of the two DNA strands  (denaturation 
step), then the creation of the link between the primers and their complementary regions of 
the filaments of denatured DNA (annealing step). Finally, the reaction of the polymerase 
(extension phase of the filament from primers 5') may start. Polymerases usually belong to 
thermophilic organism and are not inactivated by high temperatures, such as the Taq 
polymerase from the thermophilic bacterium Thermus aquaticus. This allows to realize 
more PCR cycles in sequence; in each cycle the DNA synthesized in the previous steps is 
also duplicated, obtaining a chain reaction that allows an extremely rapid multiplication of 
the genetic material of interest.  
During the denaturation step, the solution of DNA to be replicated, deoxyribonucleotide 
triphosphates (dNTPs), magnesium ions, primers and DNA polymerase, is brought to a high 
temperature (over 90° C); the double helix of DNA is cleaved and the two strands which 
constitute it are released. 
Subsequently the temperature is lowered to 40-55° C, in order to allow the binding of the 
primers to their complementary regions of the filaments of denatured DNA (annealing step).  
Finally, the temperature is raised up to 65-72 ° C in order to maximize the action of DNA 
polymerase that determines an elongation of the primers linked, using as template the 
single-stranded DNA (extension phase) (Figure 7). 
The described cycle is repeated typically for about 30-40 times. Generally the process does 
not exceed 50 cycles because at a certain point the amount of DNA obtained reaches a 
plateau. 
The greatest problem of PCR derives from its high sensitivity and efficiency; in fact, PCR is 
very sensitive to the presence of contaminant genetic material that can be found on  
instruments, on operators, or in the external environment. The major source of 
contamination is the opening of tubes containing amplified material, which can spread in the 
air as aerosols and contaminate subsequent PCR [84]. 
 
   
                          Figure 7. Thermal cycles of PCR. 
 
Post amplification detection. 
Different methods for detection after amplification are available; the choice of the right 
method is based on the characteristic of the amplified product and if there is the need to 
sequence the product. Another factor to consider is the cost of the equipment required for 
detection. In daily use, diagnostic detection of PCR products on agarose gel or by blotting 
methods are giving way to new automated methods (Real-Time PCR). 
 
Electrophresis on agarose gel. 
The agarose gel electrophoresis is a simple and fast method that allows to separate, and then 
identify, DNA fragments according to their molecular weight. The agarose gel is subjected 
to an electric field that makes the DNA migrate from the negative pole to the positive one, 
as a function of the electrical charges conferred by phosphate groups. The migration speed 
depends on the size of the fragments, the percentage of agarose in the gel and by the applied 
voltage; smaller linear fragments migrate faster than larger ones. Several types of dyes are 
used to highlight the PCR products on gel; the most widely used is the ethidium bromide, 
that is a planar molecule which fits between the bases of the double stranded DNA and 
emits fluorescent light when irradiated with ultraviolet light (300 nm). Unfortunately the 
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ethidium bromide is considered as one of the most dangerous mutagenic agents present in 
the laboratory; therefore in recent years new safer methods for staining of the agarose gel 
has been searched [84]. 
 
Capture of the amplification product. 
In this detection method, probes specific for the amplification product to detect are bonded 
to 96-well microplates or magnetic beads. During the amplification step of PCR, primers are 
linked in 5' to a molecule of biotin; the biotinylated DNA binds to the probe and, after 
several washes to remove the non-specific products, a substrate is added and the resulting 
colorimetric reaction is read at spectrophotometer [84]. 
 
Real-Time PCR. 
Real-Time PCR is a technological innovation, characterized by real-time detection of the 
amplified product and by the ability to multiple searches.  In fact, thanks to the new Real-
Time techniques, it has been  possible to develop “multiplex tests”, which allow the 
simultaneous amplification of multiple DNA sequences due to the presence, in the reaction 
mixture, of more primer pairs, each specific against a particular genomic region. In this way 
it is possible, at the same time, to identify different pathogens in the same sample or amplify 
different genomic regions of the same organism. 
In traditional PCR, in each cycle the three phases of DNA denaturation, annealing and 
extension are repeated. This process occurs inside the tubes where the target DNA and the 
mixture of primers, Taq and dNTPs, are located; the tubes are loaded at the beginning of the 
operations in the thermocycler which is able to vary continuously the temperature 
depending on the different phase of each cycle. At the end of the amplification, detection of 
PCR products is required, with the electrophoretic run on agarose gel or with methods of 
capture on plate. 
In Real-Time PCR, a single system serves both as thermocycler and as detector of the 
amplified product. The main advantage of Real-Time PCR is the reduction of contamination 
by carry-over, since amplification and detection are performed inside sealed plates or tubes 
and leakage of the amplified DNA is avoided [84]. 
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The most Real-Time PCR in commerce are based on the transfer of fluorescent energy by 
resonance (Fluorescent Resonance Energy Transfert, FRET). FRET indicates transfer of 
energy between two neighboring  molecules, which act as markers; one acts as a donor and 
the other as an energy acceptor. The acceptor may be a fluorescent molecule or a non-
fluorescent molecule able to switch off the signal of the donor (in this case is called 
quencher). The markers are attached to small DNA probes specific for the sequence of 
interest. The efficiency of energy transfer between the two markers depends on the distance 
that separates them and the degree of overlap between the emission spectrum of the donor 
and the absorption spectrum of the acceptor (quencher). DNA probes for Real-Time PCR 
with the use of a quencher are among the most widely used, because the quencher molecules 
have broad spectra of absorption with low basal levels of fluorescence: these characteristics 
allow the use of a single quencher for most donors, each with its own specific wavelength 
emission. 
The main Real-Time PCR system available today involves the use of TaqMan probes. 
This method exploits the ability as exonuclease 5 '→ 3' of Taq enzyme to generate a specific 
product that can be revealed simultaneously to the amplification. 
TaqMan probes hybridize within the target sequence; the donor (for example a molecule of 
carboxyfluorescein, FAM) is linked in 5’ of the TaqMan probe, while the quencher ( a non 
fluorescent molecule or a molecule with different fluorescence) is linked in 3’. TaqMan 
probes do not participate in the amplification because they are phosphorilated in 3’ in order 
to prevent their extension by Taq. The emission of light by the donor is blocked by its 
proximity to the quencher. During the extension phase from one of the primers, Taq cuts 
nucleotides in 5' of the TaqMan probe thanks to its exonuclease activity 5' → 3 '; thereby 
FAM is released by the quencher. Now FAM emits fluorescence, while the quencher is not 
changed by the cut. Since the exonuclease activity of the Taq only occurs if the TaqMan 
probe is attached to the target, the increase of fluorescence is directly proportional to the 
quantity of PCR products formed: the system is able to quantize the number of amplified 
fragments of DNA that are formed in the PCR reaction [84] (Figure 8).  
The evaluation of the amount of the target DNA is performed by determining the threshold 
cycle, in which the threshold value of fluorescence is reached, that is when specific 
amplification signals are separable from the background noise of the system. The number of 
cycles necessary to reach the threshold cycle is inversely proportional to the number of 
targets present in the initial sample. 
 
 
 
 
Figure 8. Operating diagram of Fluorescent Resonance Energy Transfert, FRET, with TaqMan 
probes. 
 
C. trachomatis genotyping. 
Since C. trachomatis was first isolated in 1957, extensive efforts have been made towards 
development of methods to characterize this important pathogen into different types. In the 
1960s, Wang and Grayson developed the mouse toxicity prevention test (MTPT), 
inoculating egg yolk sacs with “trachoma-inclusion conjunctivite organism”, then injecting 
extracts of these into mice. Subsequently, intravenous injection of the same or different 
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isolated of Chlamydia were repeated in the same mice and a protective mechanism in mice 
that have received the same isolated, or a partial cross-protection from other isolates, was 
reported. In this way, the authors demonstrated the presence of different kind of Chlamydia 
and classified 80 strains of Chlamydia into six immunological types [85]. 
Looking for a faster and simpler test, the same authors developed in the 1970s a 
microimmunofluorescence test, based on elementary bodies of known type grown in yolk 
sacs and polyvalent antiserum produced in mice [86]. When cellular culture became 
applicable, in the 1960s, researchers identified 13 different types of Chlamydia, according 
to the surface antigens A, Ba, B, C, D, E, F, G, H, I and L1-3 [86,87]; types Ia, J,Ja and K 
were identified later. These classification in 17 different serotypes is still in use. 
Microimmunofluorescence was hampered by cross-reactivity between related types and the 
polyclonal antibodies were later replaced by more specific monoclonal antibodies. It was 
recognized that the main epitopes for antibodies were located on the MOMP (Major Outer 
Membrane Protein)  and all the subsequent typing procedures were based on this protein or 
on the gene omp1 encoding for it. 
Then, new tests based on monoclonal antibodies were developed and antibody panels 
became commercially available; the first studies on tissue tropism of serovars were 
published. 
All the above mentioned techniques require culture of C. trachomatis, which is expensive 
and time consuming. Moreover, serovars unrecognized by the antibody panels might evolve 
and change over time. Finally, sensitivity of culture is often less than for the NAAT assays 
[88]. 
 
PCR and Restriction Fragment Lenght Polymorphism (RFLP). 
With the invention of PCR in 1983, the era of genotyping began. In the 1990s, PCR was 
often followed by RFLP, with DNA patterns resolved on gel. The patterns were found to be 
compatible with the results obtained with serotyping. In 1991, Rodrigez et al amplified 
1200 bases of the omp1 gene and the product was digest by restriction nuclease and 
resolved on polyacrylamide gels [89]. Thirteen of the 15 serovars could be differentiate by 
this technique; from there, several studies extended and improved batteries of restriction 
enzymes. 
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Omp1 is a single copy gene and to obtain adequate material for RFLP, PCR was improved 
using nested primers. A nested PCR consists in a second PCR carried out on the products of 
the first PCR, using primers complementary to regions of the same DNA fragment, but 
more internal compared to the regions of annealing of the first primer pair. 
In the first report about RFLP, it was point out that serovar E is the most prevalent type in 
heterosexual population, followed by serovars D and F. On the contrary, in MSM, the 
prevailing serovars are G, D and J. 
From 1993, it was shown that PCR, and subsequent typing, could be made directly from 
biologic samples, avoiding the need to use cell culture. 
The strength of PCR and RFLP method is its ability to detect mixed infections; this ability 
has been overestimated in the past, in fact PCR tend to favor the most represented serovar 
and the others may remain undetected. The drawback of this method is that it does not allow 
for identification of single nucleotide changes, which are the most predominant variations in 
omp1. 
PCR and RFLP are still often used, also for diagnosis of LGV [88]. 
 
PCR and sequencing. 
With automation and the availability of fluorophore-marked nucleotides, it  has become 
possible for routine laboratories with no culture facilities to perform sequencing. It has been 
shown that sequence determination of omp1 provided a higher resolution than serotyping 
and RFLP [90,91,92]. The main drawbacks of sequencing are the difficulty in identifying 
mixed infections and the inadequate ability to discriminate between different genotypes, 
because peaks from different PCR products will be superposed in the chromatograms from 
sequencing reactions. These defects do not make it suitable as a reference method for 
genotyping in unselected populations. In a recent study, Simpson’s index of diversity (D) 
for omp1 has reported to be 0.69, an extremely lower value than the 0.95 required by the 
guidelines of the European Society of Clinical Microbiology and Infectious Disease 
(ESCMID) and the European Study Group on Epidemiological Markers (ESGEM) for a 
typing system [88]. 
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Other typing methods. 
Other methods have been developed for genotyping of C. trachomatis using omp1 as target.  
- For the three L-serovars, genotyping has been enabled by Real-Time PCR targeting 
the omp1 gene and an L-serovar specific gap in the polymorphic protein H (pmpH). 
Differentiation between the three L-serovar is obtained by a second Real-Time PCR 
targeting the serovar-specific regions of the omp1. The main advantage of this 
method appears to be the ability to detect multiple infections, but on the other hand 
two consecutive PCR must be carried out for a complete genotyping [93]. 
- Pulsed field gel electrophoresis (PFGE) requires pure bacterial DNA taken from 
Chlamydia culture and purified from the host DNA. This method has been used to 
create a genetic map of the serovar L2 [94], but they have minor ability to 
discriminate against the different strains than serotyping and genotyping based on 
gene omp1. 
- Random amplification of polymorphic DNA (RAPD), despite not reflecting the 
serotyping, can be used as a supplement to omp1 typing [95]. 
- The technique of amplified fragment length polymorphism (AFLP) uses restriction 
enzymes to cut the genomic DNA, followed by amplification of restriction fragments 
then displayed on gel. This method requires the culture of the genomic DNA and 
purification of the elementary bodies; it is not easy to reproduce [91].  
- The Microsphere Suspension Array allows the identification of more than 100 
biomolecules, including proteins and nucleic acids. When accompanied by a 
multiplex PCR with a sensitivity comparable to the single-plex assay, with a high 
number of primers, the system is simple to use, inexpensive and allows to optimize 
time compared to the PCR followed by sequencing, allowing also to identify multiple 
infections [96]. 
- A low-resolution typing system has been developed thanks to the Reverse Line Blot 
assay, which allows a faster and less laborious genotyping compared to gene 
sequencing, but may miss subtle changes in omp1, for example point mutations, that 
are the most frequently found alterations in this gene [88]. 
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None of the tested target genes provide sufficient discrimination of C. trachomatis strains, 
and there is need for better genotyping system. Two recent alternative detection system 
seemed to provide high resolution typing of C. trachomatis. 
- A combination of PCR and sequencing of omp1 plus three loci of VNTR (Variable 
Number Tandem Repeat, that are repeated stretches of the same nucleotide or motifs) 
is called MLVA (multiple loci variable number of tandem repeats analysis); this 
approach gets  a Simpson’s index of diversity of 0.94, very close to the 
recommended value of 0.95.  This method is by far more discriminative than omp1 
alone (D=0.69) but, such as other PCR and sequencing assays, is unable to detect 
mixed infections. The analysis of VNTR targets will result in high resolution power 
especially for short-term, local epidemiology, since in these areas of repetition DNA 
polymerase is prone to error during replication. However, MLVA is rarely used as a 
diagnostic method for routine, playing an important role as a final method when 
other typing methods have failed [97]. 
- The multilocus sequence typing (MLST) is a genotyping method based on 
amplification and sequencing of several genetic regions. The previous studies and 
systems based on single genes as targets for typing have shown serious limitations 
due to the low variation of sequences, probably due to the genetic isolation of 
Chlamydia and the low degree of horizontal gene transfer during evolution. MLST 
systems have been developed to understand the genetic structure of the population 
and to evaluate the association between genotype and disease. A kind of MLST 
reported by Klint et al, includes 5 highly variable gene regions; 2 of them (penicillin-
binding protein and histone H1–like protein [hctB]), are subjected to selection 
pressure, which facilitates the analysis of epidemiologic changes over limited 
periods[98]. Albeit with some limitations, this system can be used on clinical 
samples from NAAT diagnostic and possesses a discriminatory ability high enough 
to be used to study the contact-tracing. 
An alternative MLST system has also been based on 7 housekeeping genes and 
analyzes evolutional changes rather than acting as a tool for partner notification [88]. 
- Multilocus Typing DNA Microarrays, an alternative technique to MLST, has been 
proposed recently. It is a faster and cheaper system and it proves to have a detection 
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capability which is  almost twofold higher than typing base on omp1; moreover it 
allows identification of mixed infections. 
 
All the techniques described above and actually used require the amplification of a target by 
a PCR and therefore depend on it in terms of sensitivity and specificity. 
Despite the important epidemiological knowledge which has been obtained through 
serotyping, genotyping based on PCR and sequencing of omp1 is now replacing serotyping. 
The insufficient epidemiologic resolution achieved by characterization of omp1, makes it 
necessary to apply new genotyping methods, as MLVA or MLST. However, it is important 
to underline how the culture of C. trachomatis can still play an important role in the 
identification and characterization of new variants and how the methods of typing based 
only on omp1 are still often used for studies of molecular epidemiology [88]. 
The main features of the different methods of typing are schematically summarized in 
Figure 9. 
 
Finally, these are the principal hand points and reasons for typing [88]: 
- to study the transmission pattern in sexual networks  
- to be used as a tool in partner notification 
- to enable association with clinical manifestations and pathogenicity 
- to study association between specific serovars and tissue or organ affinity 
- as an aid in cases of sexual abuse 
- to help determine whether infections are persistent or new 
- to monitor treatment outcomes 
- to develop future vaccines 
- for evolutionary surveillance of specific clones. 
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Method  Mechanism  Target  Reference  Culture  Comment 
MTPT  Immunization  Unknown 
Wang & Grayston 
(1963) 
NA 
Proof of existence of 
different types 
Microimmunofluorescens  Immunization  MOMP  Wang et al. (1975)  NA 
Cross‐activity between 
types 
Polyclonal antibodies  Serotyping  MOMP  Wang et al. (1973b)  Y 
Cross‐activity between 
types 
Monoclonal antibodies  Serotyping  MOMP 
Stephens et al. 
(1982) 
Wang et al. (1985) 
Y 
Cross‐activity between 
types 
RIA  Serotyping  MOMP 
Van Der Pol & 
Jones (1992) 
Y 
Cross‐activity between 
types 
Dot‐ELISA  Serotyping  MOMP  Barnes et al. (1987)  Y 
Cross‐activity between 
types 
PCR‐RFLP  Genotyping  Omp1 
Rodriguez et al. 
(1991) 
Y  13 of 15serovars identified 
PCR‐RFLP  Genotyping  Omp1 Lan et al. (1993) Y Cervical scrapes used
PFGE  Genotyping 
Genomic 
DNA 
Birkelund & 
Stephens (1992) 
N  Purification of EBs needed 
RAPD  Random DNA 
Genomic 
DNA 
Scieux et al. (1993)  NA  Not reflecting serovars 
PCR  Genotyping  Omp1 
Pecharatana et al. 
(1993) 
Y 
Fluorophore marked
primers 
Only serotypes A, B, C 
detected 
AFLP  Genotyping 
Genomic 
DNA 
Morre et al. (2000)  NA  Difficult to standardize 
Reverse line blot  Genotyping  Omp1 Quint et al. (2007) Y Low technology detection
PCR+sequencing  Genotyping  Omp1 Lysen et al. (2004) N Serotype‐level typing
Real‐time PCR  Genotyping 
Omp1
Pmp‐H 
Schaeffer & 
Henrich (2008) 
Y  Only L‐serovar 
PCR+sequencing  Genotyping  MLST Klint et al. (2007) N Subtyping serovars
PCR+sequencing  Genotyping 
Omp1
VNTR 
Pedersen et al. 
(2008) 
N  Subtyping serovars 
Suspension array  Genotyping  Omp1 Huang et al. (2008) Y Serotype‐level typing
High resolution Melting 
analysis 
Genotyping  Omp1  Li et al. (2010)  N 
Serotype‐level
typing 
Microarray analysis  Genotyping  Omp1 
Christerson L et    
al. (2011) 
Ruettger A et al.    
(2011) 
N 
Serotype‐level typing 
Identifies mixed infections 
Figure 9. The main features of different methods for typing (MTPT Mouse toxicity prevention test ; 
RIA Radio immunoassay; ELISA Enzyme-linked immunoadsorbent assay; RFLP Restriction 
fragment length polymorphism; PFGE Pulsed-field gel electrophoresis; RAPD Random 
amplification of polymorphic DNA; AFLP Amplified fragment length polymorphism; NA non 
applicable). 
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EXPERIMENTAL SECTION: OUR EXPERIENCE IN THE 
BOLOGNA AREA. 
 
Since 2009, routine diagnosis of Chlamydia trachomatis and Neisseria gonorrhoeae 
genitourinary infection in  patients attending the Clinic of Sexually Transmitted Disease 
(STD), Dermatology Section , Sant' Orsola-Malpighi Hospital, Bologna has been carried out  
by a commercial Real-Time PCR (VERSANT® CT/GC 1.0 Assay). The Section of Clinical 
Microbiology of our hospital has developed a home-made PCR test recently in order to 
typify C. trachomatis serovars non-L and serovars L.  
So far, the diagnosis of lymphogranuloma venereum (LGV) for patients attending our Clinic 
has been based  on clinical symptoms and signs and it has been supported by chlamydial-
specific serology; an etiologic diagnosis of certainty has not been  possible. The assessment  
of response to the treatment was also mainly based on the resolution of clinical symptoms. 
The development of the new diagnostic technique allows a diagnosis of certainty of LGV 
through identification and typing of C. trachomatis serovars L. 
The purpose of our study is to use the new diagnostic test to identify accurately LGV 
infection in our patients, also in relation to the ongoing outbreak of LGV proctitis in MSM 
in  industrialized countries. The diagnosed cases of LGV will be described and compared 
with the international literature. 
 
Patients and methods. 
From January 2012 to January 2013, patients attending our STDs Clinic complaining of 
rectal disorder or simply with a positive anamnesis for unprotected anal intercourse in the 
last 6 months were asked to carry out a clinical visit, a rectal swab and a sample of urine to 
detect  C. trachomatis and N. gonorrhoeae infections using a Real-Time PCR (VERSANT® 
CT/GC 1.0 Assay). All positive samples  for Chlamydia were typified with a home-made 
PCR to identify the specific serovar.  
During the clinical visit, the external genitalia, perianal skin and anal mucosa were 
evaluated; in particular the presence of perianal ulcerations, anal discharge and inguinal 
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lymphadenopathy were assessed. If genital or perineal ulceration were present, HSV 
infection were evaluated with Tzank smear examination.  
All patients underwent a complete blood screening for the main STDs (HIV, HBV, HCV, 
syphilis) and for chlamydial serology (anti-Chlamydia IgA ang IgG determined with an 
immunoenzimatic test).  
Furthermore, personal details (sex, age, nationality), data about subjective urogenital and 
gastrointestinal symptoms, sexual behavior, habit of using condom, number of sexual 
partners in the last 6 months and previous STDs were collected for each patients. 
Patients with LGV were treated and re-evaluated with clinical examination and laboratory 
tests (VERSANT® CT/GC 1.0 Assay on urine and anorectal swab, chlamydial serology) 3 
months after the antibiotic treatment. 
Patients took part in this study after having given  their consent. 
 
Diagnosis of C. trachomatis infection with Real-Time PCR. 
VERSANT® CT/GC 1.0 Assay (Siemens Healthcare Diagnostics, USA), based on a 
procedure of kinetic PCR (kPCR), is a fully automated qualitative in vitro test for the 
detection of nucleic acids of C. trachomatis (CT) and N. gonorrhoeae (GC) in clinical 
samples of both symptomatic and asymptomatic patients [99]. 
The VERSANT kPCR system is composed of a module for the preparation phase and a 
module for amplification, managed by a dedicated software (Figure 10). The extraction 
phase is totally automated and works binding the nucleic acids to the surface of magnetic 
beads coated with silica. In the module for the extraction the automated dispensing of the 
mixture of primers, probes, dNTPs and enzyme Uracil DNA Glycosylase AmpErase ™ 
UNG (1 unit / mL) also takes place in order to diminish the environment contamination by 
the amplified products. Moreover, during the extraction phase, proteinase K inactivates the 
DNAse and lyses the bacterial cell allowing the release of DNA. The DNA released from 
bacterial particles, along with other nucleic acids and internal control specially added, binds 
to silica of the magnetic beads. A number of successive washes remove the unwanted 
components of the sample. The purified DNA is eluted and subsequently loaded into a 96-
well plate for the execution of the kPCR. 
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A mixture of probes (Taqman), primers and dNTPs is added to each well. The nucleotide 
bases A, G, C and U, instead of the traditional base T, are contained in the mixture. The 
target sequences of C. trachomatis, as well as the internal control DNA, are amplified and 
detected simultaneously during the Real-Time PCR. Chlamydia TaqMan PCR primers and 
probes were designed to target the Gen Bank nucleic acid sequence of the 7.5 kb cryptic 
plasmid outside of 377 bp deletion, being so able to identify also the nvCT mutant [99].  
In the preliminary phase, the enzyme Uracil DNA Glycosylase AmpErase ™ UNG is left to 
act for 10 minutes at 50°C, then it is inactivated for 15 minutes at 95°C. After this, the real 
PCR begins and it is repeated for 40 cycles. 
Each cycle consists of two parts: during the first one, at 95°C for 15 seconds,  denaturation 
of nucleic acids occurs; during the second one, at 62°C for 1 minute, annealing and 
elongation of the sequences to be amplified take place.  
The probes include fluorescent tracers and quenchers as modifiers. The probes, labeled in 
this double way, specifically detect the presence of amplified originated from C. trachomatis 
and of the internal control during the PCR. In their native state, the probes adopt a folded 
state which positions the quencher near the fluorescent dye. In this condition, most of the 
fluorescence of the tracer is absorbed by the near quencher, thus minimizing the 
fluorescence emitted.  When the amplified are generated, the fluorescent marked probes 
unfold, they hybridize with the new amplified DNA, and so they separate the fluorescent 
tracer from its quencher and develop a strong emission of fluorescence. During the 
extension phase, some of the hybridized probes are cut by the exonuclease activity of the 
polymerase and are released in solution, so their brightness continues to be detectable. The 
combined fluorescence of both cut and linked probes correlates with the amount of 
amplified generated, and it is proportional to the amount of DNA of C. trachomatis in the 
sample. At each cycle, the luminescence of each sample during the exponential phase of 
PCR is detected. 
 
 
 
         Figure 10. VERSANT kPCR scheme. 
 
Finally, the computer processes the data of the fluorescence for each sample providing an 
amplification curve and, in case of positivity, the output cycle. According to what has been 
observed so far, cycle of output appears inversely proportional to the amount of starting 
DNA (the higher the output cycle, the smaller the amount of starting DNA). At the end of 
the PCR, the amplification of the internal control, which is designed to get out during the 
last cycles, must be obtained for each sample.  
 
Typing C. trachomatis with Home-made PCR and RFLP. 
The epitopes that characterize different serotypes of C. trachomatis mainly reside on 
MOMP. The gene encoding for MOMP, called omp1 or OmpA, is the main target of the 
genotyping process, analyzing the changes of the gene sequences within the different strains 
[100]. 
The omp1 gene is amplified by the extracts deriving from the residual on the extraction 
plate of the module VERSANT® kPCR after the session of diagnostic commercial PCR. 
These extracts are submitted to a semi-nested PCR arranged according to the literature 
[101,102]. 
 
This method consists of a first session of PCR in which a fragment of 1033 bp DNA omp1 
gene is amplified, using the primers SERO1A (constituted by the base sequence 5'-
38 
 
ATGAAAAAACTCTGAAATCGG-3') and SERO2A (sequence 5'-
TTTCTAGAT/CTTCATT/CTTGTT-3'). These primers are both specific for Chlamydia and 
able to recognize all strains of the bacterium, binding to the complementary regions of the 
gene omp1. The presence of an amplified of 1033 bases of the gene omp1 is an index of 
positivity, since the sequence bound by the primers is specific for this bacterium. For this 
amplification step, 15 µl of extract were added to a final volume of 50 µl of the reaction 
mixture, containing: 
- 1.6 µl of primer SERO1A 10 µM 
- 1.6 µl of primer SERO2A 10 µM 
- 10 µl of buffer 5× 
- 2 µl DMSO 
- 5 µl of dNTPs 2 mM 
- 0.4 µl of Taq polymerase (5U/μl) 
- 2 MgCl2 25 mM 
- 12.4 µl of H2O 
PCR amplification is carried out as described below: 
- 7 min at 94º C (pre-activation of  the Taq polymerase) 
- 1 min of denaturation at 94º C 
- 3 min of annealing at 45° C                 40 cycles 
- 3 min of elongation at 72º C 
- 7 min at 72º C for an additional extension 
  
The second session of PCR has as target the same amplified obtained from the previous 
procedure, and not the extracts from the commercial kit, thus increasing the sensitivity of 
the entire method, giving the possibility of genotyping biological samples containing a low 
charge of bacteria. The conditions for amplification are identical to those previously 
described, but the DNA fragment used as target of the second PCR is 55 bp shorter than the 
1033 bp fragment of the previous procedure. In fact, a different primer pair (one nested 
primer,pCTM3, sequence 5'-TCCTTGCAAGCTCTGCCTGTGGGGAATCCT-3' and 
SERO1A) is used compared to the first session; this second primer pair binds the amplified 
DNA a little more inside, slightly shortening it. 
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           Figure 11. Nested-PCR. 
 
This technique is a semi-nested PCR rather than a true nested PCR, because the two 
sessions differ only for a primer and not for both (Figure 11). 
The reaction mixture of the second session of PCR contains 5 µL of target DNA unlike 15 
µl of the previous session, and therefore different amounts of H2O to bring the final volume 
to 50 µl, as described below: 
- 1.6 µl of primer PCTM3 10 µM 
- 1.6 µl of primer SERO2A 10 µM 
- 10 µl of buffer 5× 
- 2 µl DMSO 
- 5 µl of dNTPs 2 mM 
- 0.4 µl of Taq polymerase (5U/μl) 
- 2 MgCl2 25 mM 
- 22.4 µl of H2O 
 
Genotyping continues with the use of Restriction Fragment Length Polymorphism 
(RFLP) which exploits the capacity of restriction enzymes to 'recognize' and cut the omp1 
gene previously amplified in a specific way depending on the different bacterial strain. 
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In order to ensure further validity to the method, the amplified obtained by nested PCR is 
detected using the electrophoretic run on agarose gel at 1.5% (in particular 1.5 g of agarose 
in 100ml of buffer 0.5 X TAE), before digestion by restriction enzymes, thus confirming the 
presence of amplified genetic material, in order to endorse the proper execution of both 
molecular methods. 
RFLP provides the digestion of 10 µl of the nested PCR product with 2.5 U of restriction 
enzyme AluI (Promega, Madison, WI); if the action of digestion of AluI is not sufficient, or 
if it is not possible to recognize different strains with the sole activity of this enzyme, 
restriction enzymes DdeI, HinfI and EcoRI can be used,  evaluating their activity on part of 
the amplified previously stored. 
The conditions of digestion can be summarized as follows: 
- 10 µl of amplified 
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- 0.25 µl of AluI (2.5 U) 
- 2 µl of buffer 10x                   digestion over night at 37 º C 
- 0.2 µl of BSA 100x 
- 7.5 µl of H2O 
The product of digestion is subsequently examined by analyzing its electrophoretic run for 
45 minutes at 100 V on 12% polyacrylamide gel stained with ethidium bromide. According 
to the weight and the number of different fragments generated by cutting, the patterns of 
restriction, and  therefore C. trachomatis genotypes, are identified (Figure 12,13,14). 
 
Figure 12. Restriction 
patterns on polyacrylamide 
gel after enzymatic 
digestion. 
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 to UV light. 
Figure 13. The DNA stained with 
ethidium bromide emits a red-orange 
fluorescence when subjected
 
 
 
 
 
 
 
 
Figure 14. Restriction patterns resulting from the action of the enzymatic digestion for each C. 
trachomatis serovar, according to the use of different restriction enzymes (AluI, DdeI, HinfI and 
EcoRI). 
AluI 
A B Ba C D Da E F G H I Ia J Ja K L1 L2 L2a L3 
486 244 265 442 241 239 241 321 321 458 458 458 435 442 486 241 227 227 458 
295 225 204 241 225 225 225 256 207 298 295 298 298 298 213 228 225 225 298 
138 195 195 217 195 195 132 207 193 138 138 138 138 138 138 204 132 131 138 
46 89 150 57 68 68 102 101 107 46 46 46 46 46 71 68 102 101 46 
33 68 88 28 61 60 96 73 96 33 33 33 44 33 46 61 96 96 33 
11 61 68 16 56 56 68 33 73 28 28 28 33 28 33 56 59 59 28 
10 56 33 11 42 42 56 10 10 11 11 11 11 16 14 42 56 56 11 
 33 10 10 41 41 42 9 9 10 10 10 10 11 11 41 48 48 10 
 32   33 33 17 6     7 10 10 21 17 17  
 10   32 32 15         17 15 17  
    10 10 10         15 10 15  
     6          10  10  
               6  9  
 
DdeI 
A B Ba C D Da E F G H I Ia J Ja K L1 L2 L2a L3 
323 293 293 414 435 434 369 605 605 414 323 323 414 414 414 320 293 193 414 
231 251 251 323 293 292 293 411 385 323 231 231 323 323 288 293 164 164 323 
183 187 187 153 282 281 184  26 153 183 183 153 153 153 282 150 150 153 
150 150 150 132   164   132 149 153 132 132 132 115 132 131 132 
132 132 132        132 132   35  115 115  
                87 87  
                72 72  
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HinfI 
A B Ba C D Da E F G H I Ia J Ja K L1 L2 L2a L3 
530 591 591 998 392 391 588 764 817 533 529 533 533 533 557 588 591 590 533 
465 237 238 24 237 236 237 175 175 465 465 465 441 465 441 237 237 237 465 
24 161 161  196 195 161 53 24 24 24 24 24x2 24 24 161 161 161 24 
 24 24  161 161 24 24        24 24 24  
    24 24              
 
EcoRI 
A B Ba C D Da E F G H I Ia J Ja K L1 L2 L2a L3 
963 826 826 963 823 820 328 960 629 966 962 965 966 966 966 823 498 498 835 
56 131 131 56 131 131 269 56 331 56 56 56 56 56 56 131 328 327 131 
 56 56  56 56 226  56       56 131 131 56 
      131          56 56  
      56             
 
 
Results. 
During the study, 84 anorectal swabs for CT/GC PCR were performed on 6 women and 78 
men. VERSANT® CT/GC DNA 1.0 Assay identified 14 positive samples  for C. 
trachomatis; typing with semi-nested PCR and RFLP identified 6 serovars L2 in 5 patients 
(one of the patients reported 2 different infections by C. trachomatis serovar L2), 2 serovar 
E and 1 serovar J. It was not possible to typify 5 of the positive samples because of the low 
presence of chlamydial DNA in the sample itself.  
The patient with CT serovar J infection was positive also for GC infection. All positive 
patients were MSM. 
Features and clinical history of the 5 patients with LGV proctitis are summarized below 
(Figure 15,16,17). 
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Patients  Proposed 
examination 
Results First treatment Outcome
1  Screening STDs 
Anal swabs for CT/NG 
Urine for CT/NG 
Rectal swabs + Doxycyclina Healing
2  Abdomen US  Monolateral
inguinal 
lymphadenopathy 
Brivudine/
acyclovir 
No
improved
3  Endoscopy  Internal hemorroids Ciprofloxacin Slight 
improved
4  Endoscopy 
(colonscopy) 
Anal and sigma 
mucosal ulceration 
Mesalazine/
prednisolone 
Slight 
improved
5  Proctosigmoidoscopy 
Transanal US 
Rectal warts
Internal hemorroids 
Surgery/
diosmin 
No
improved
Patients  Anal 
ulceration 
Anal 
pain 
Anal 
discharge 
Constipation
Tenesmus 
Inguinal
lymphadenophaty 
First
consultation 
Diagnostic
hypothesis 
1  x  x  X  X x STDs clinic  Syphilis 
CT/NG proctitis
Trauma 
2  x  x    X x Primary care 
 physician 
HSV 
3  x  x  X  X Primary care 
 physician 
Enteritis 
4  x  x  X  Primary care 
physician 
IBD 
CMV 
Solitary ulcer 
5    x  X  X Primary care 
physician 
IBD 
 
Figure 15. Summary of clinical symptoms and diagnostic pathway of the patients. 
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Patients  Age  Sexual 
behavior 
N°partner 
last 6 mo. 
Condom Other
STDs 
HIV Viral load  CD4+  CD4/CD8
1  39  bisex  6  Sometimes Syphilis
GC urethritis 
HBV 
 
2  42  MSM  >10  No Syphilis
Perianal warts
HSV/ HBV 
x <20copies/ml  834  0,71
3  43  MSM  >5  No Syphilis x <20copies/ml  859  0,29
4  48  MSM  1  No Syphilis x <20copies/ml  549  0,65
5  44  MSM  ¾  Sometimes Anal warts  
 
Figure 16. Summary of sexual behavior and co-infection with other STDs. 
 
Patients  PCR  Exit 
cycle 
Time for
diagnosis
Antibodies 
U/mL 
Treatment Outcome Time 
for 
clinical 
healing 
PCR 
after 3 
months 
Antibodies 
U/mL 
after 
3months 
Only if symptoms 
recur 
Rectal
PCR  
Antibodies
U/mL 
 
1  Rectal 
swabs+ 
Urine ‐ 
31,5  1 month IgA 7 
IgG 39 
Doxycycline
100 mg 
x2/die 
21 days 
Healing ̴10 
days 
CT‐LGV 
neg 
 
CT/GC 
pos 
IgA 6 
IgG 57 
2  Rectal 
swabs+ 
Urine‐ 
21,62  2 months IgA 12 
IgG 18 
Doxycycline
100 mg 
x2/die 
21 days 
Healing ̴10 
days 
CT‐LGV 
neg 
 
IgA 8 
IgG 19 
CT‐LGV 
pos 
NG pos 
 
(after 9 
months)
IgA 7
IgG 37 
 
(after 9 
months) 
3  Rectal 
swabs+ 
Urine‐ 
32,83  1 months IgA 42 
IgG 52 
Doxycycline
100 mg 
x2/die 
21 days 
Healing ̴15 
days 
CT‐LGV 
neg 
 
IgA 37 
IgG 58 
4  Rectal 
swabs+ 
Urine‐ 
26,41  11 
months 
IgA 8 
IgG 86 
Doxycycline
100 mg 
x2/die 
21 days 
Healing ̴12 
days 
CT‐LGV 
neg 
 
IgA 5 
IgG 112 
5  Rectal 
swabs+ 
Urine‐ 
25,7  23 
months 
IgA 8 
IgG 60 
Doxycycline
100 mg 
x2/die 
21 days 
Healing ̴20 
days 
CT‐LGV 
neg 
 
IgA 7 
IgG 98 
 
Figure 17. Summary of laboratory results at the time of diagnosis and after treatment. 
Clinical presentation. 
All patients with LGV proctitis were symptomatic when visiting  our Clinic. All of them 
complained of anal pain, occurred with  change in bowel habit, like constipation or 
tenesmus (4 patients), and mucous or bloody anal discharge (4 patients). During clinical 
examination anal or perianal ulceration were noticed in 4 patients: they were of small size 
and their edges were not infiltrated (Figure 18). Only in 2 patients a monolateral, not 
painful, inguinal lymphadenopathy was appreciable (Figure 19)(Figure 15). 
 
 
Figure 18. Perianal non infiltrated ulceration in a patient with LGV proctitis. 
 
46 
 
 
Figure 19. Monolateral inguinal lymphadenopathy in a patient with LGV proctitis. 
 
Recent medical history. 
Only one patient (patient n°1) came quickly to our Clinic because he already knew it; after a 
few weeks, the time necessary for the laboratory results, diagnosis of LGV proctitis was 
established.  
The other patients firstly asked advice to their primary care physician.  
Patients n° 2, presenting perianal ulceration and inguinal lymphadenopathy, after 
undergoing an abdominal ultrasound that confirmed inguinal lymphadenopathy, received a 
diagnosis of perianal herpes simplex infection and was treated with acyclovir and brivudine 
without any improvement. 
Patients n° 3 underwent a proctological consultation and a rectal endoscopy that revealed 
only inflammation of the internal hemorrhoidal plexus; he was treated with ciprofloxacin for 
6 days with slight improvement and after 1 month he came to our Clinic. 
Patient n° 4 complained of anal symptoms for 11 months, before having the right diagnosis. 
During this time he underwent colonscopy that revealed a widespread recto-sigmoiditis with 
multiple ulcerations; histological examination of the affected mucosa showed alterations of 
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the glandular morphology, ulceration of the mucosal surface, cryptitis and lymphocytic 
infiltrate in the lamina propria, suggesting Crohn's disease. Patients was treated with 
prednisolone and mesalazine for several weeks without any improvement. A 
Cytomegalovirus reactivation, since patient was HIV-positive, and a solitary rectal ulcer 
were the subsequent diagnostic hypotheses. 
Patients n° 5 reported the beginning of anal symptoms in July 2010; during the 23 months 
from the onset of the symptoms to diagnosis, he underwent proctosigmoidoscopy that 
revealed inflammation of internal hemorrhoidal plexus and rectal warts. Warts were treated 
surgically; inflammation of hemorrhoids did not improve with several cycles of oral 
diosmin. A following proctosigmoidoscopy showed wound healing difficulty in the seats of 
previous surgery (Figure 15). 
 
Risk factors. 
The age of patients ranged from 39 to 48 years old; the mean age was 43,2 years. 
Four patients were MSM, while one patient declared to be bisexual; all of them reported 
receptive anal intercourses in the last 6 months. Three patients declared they never used 
condom, while 2 patients used condom rarely . 
Three patients remembered more than 5 sexual partners in the last 6 months; patient n° 4 
reported a stable relationship with only one partner. 
All patients suffered from other STDs in the past. Four of them presented a positive 
serology for syphilis (2 with early latent syphilis and 2 with previously treated syphilis); 2 
patients reported a positive anamnesis for perianal or anal warts; 2 had hepatitis B; one had 
herpes virus genital infection and one a previous episode of gonococcal urethritis.  
A few months after diagnosis and treatment of LGV, two patients reported a new sexually 
transmitted infection: patient n°1 was affected by  proctitis caused by C. trachomatis non-L 
and N. gonorrhoeae 3 months after, while patient n° 2 presented a new LGV infection 9 
months after the first episode. 
Three patients were HIV-positive. All of them had a well-controlled infection with viral 
load < 20 RNA copies/mL; two patients underwent  a treatment with HAART (Figure 16). 
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Laboratory data and outcome. 
All patients with LGV proctitis had a positive rectal swab for C. trachomatis serovar L2; 
CT/NG PCR on/in urine was negative. The PCR exit cycle was  relatively low for patients 
n° 2, 4 and 5; it indicated that the starting material contained abundant chlamydial DNA. In 
patients n° 1 and 3 the exit cycle was high, indicating a low presence of bacterial DNA in 
the swabs; it could be due to the time and modality used in the collection of the sample. 
All patients were treated with doxycicline 100 mg twice a day for 21 days; all of them 
completed the treatment without side effects. Clinical symptoms and signs completely 
recovered during treatment. After 3 months the rectal swab for CT/NG PCR was negative in 
all patients, except patient  n°1 who  resulted positive for N. gonorrhoeae and C. trachomatis 
serovar non-L proctitis, with recurrence of mild anal symptoms (mucous discharge). Patient 
n°2 came back to our Clinic after 9 months from the first diagnosis of LGV because of 
recurrence of anal ulceration and pain; a new rectal swab was positive for N. gonorrhoeae 
and C. trachomatis serovar L2, witnessing a LGV re-infection. 
Serum antibodies against Chlamydia were positive in all patients, with very different values; 
IgA ranged from 7 to 42 U/mL, while IgG ranged from 18 to 86. At the control visit after 3 
months, IgA slightly decreased and IgG were stable or slightly increased (Figure 17). 
 
Discussion. 
In the last decade, a new outbreak of LGV proctitis mainly in MSM has been registered in 
the industrialized countries. LGV recurrence represents a public health problem, as its 
ulcerative nature may facilitate transmission of HIV and other STDs [67]. Diagnosis of 
LGV is not easy and requires specific diagnostic test not available in all laboratories; 
therefore, LGV is often misdiagnosed by primary care physicians and doctors who do not 
deal daily with STDs. Moreover, in many countries there is no effective surveillance system 
for this disease and data about epidemiology are uncertain. This re-emerging disease 
requires greater attention and resources. 
Since January 2012, patients attending our STDs Clinic for anorectal symptoms or simply 
with a positive anamnesis for unprotected receptive anal intercourse in the last 6 months 
have been proposed to carry out a clinical visit, an anorectal swab and a sample of urine for 
detection of C. trachomatis and N. gonorrhoeae infections using a Real-Time PCR. Positive 
50 
 
samples for C. trachomatis underwent genotyping; in this way 5 cases of LGV proctitis, and 
a re-infection in one of the patients, were diagnosed. 
 
Prevalence of LGV in the group of tested patients is 7,1%. It must be considered that we 
screened a high risk population where most of the patients complained of anorectal 
symptoms and so they were more motivated than others to undergo clinical visit and rectal 
swab. Our purpose was not to develop an epidemiological study to determine incidence and 
prevalence of LGV. In this case the study should have been performed on a larger 
population both symptomatic and asymptomatic; it is not easy to propose a rectal swabs as a 
screening test, partly because this exam assumes that the patient had passive anal 
intercourse. Some MSM may avoid seeking healthcare because they expect disapproval 
regarding their sexual behavior and the sanitary staff is not always able to ask behavioral 
screening questions in a professional manner, without implicit assumptions [103]. 
Therefore, statistical prevalence of LGV in our samples cannot be considered a pure 
epidemiological value and it is difficult to compare it with other works that reported a 
prevalence value of about 1% in MSM patients attending a genitourinary clinics [38,39].  
 
The mean age of our patients was 43,2 years, in line with the epidemiologic data of ECDC 
that described the greatest number of cases in the age category 35-44 years old, followed by 
the 25-34 years old. By contrast, the incidence of C. trachomatis non-L infection is higher in 
the age group 20-24 years old [37]. 
 
Our cases of LGV infections presented in MSM or bisexual men, and this is in line with 
European data [37]. In fact, in all industrialized countries, LGV proctitis has been described 
almost exclusively in MSM and the detection of LGV in the general population has not been 
confirmed up to now [63], if not for some sporadic cases [54,55]. 
 
The majority of patients reported high-risk sexual behavior including a high number of 
sexual partners, unprotected anal intercourse, fisting, sharing sex toys, behaviors often 
connected to a sex party scene and involving international sexual networks. In a cross-
sectional study the use of enemas was found to be associated with a higher risk of LGV 
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proctitis, probably because this procedure leads to mucosal damage before receptive anal 
intercourse favoring the transmission of the disease [67]. Information about sexual behavior 
in our patients only concerns the use of condom, that is never or only sometimes used by 5 
men previously described, and the number of sexual partners in the last 6 months. Four 
patients reported they have had multiple sexual partners, although the number vary from 
case to case, while patient n°4 reports a stable relationship for years.  
He and his partner reported unprotected sex with each other, passive to our patient, who is 
HIV-positive, and active for his partner, and both denied having had sexual relations outside 
the couple. The serological evaluation of the partner, HIV negative, showed an antibody 
titre equal to 8 U / ml for IgA and 110 U / ml for IgG, suggesting a previous contact with 
the bacterium. However, the lack of a rectal swabs and urine sample for PCR does not allow 
us nothing more than a hypothesis, also because the partner was asymptomatic throughout 
the period of study. Evaluating the information provided by the couple, the presence of a 
high antibody titre and the lack of appearance in the partner may suppose a case of urethral 
asymptomatic LGV in the partner, unknowingly transmitted to our patient.  
It is also interesting to note that patient n°5 reported a relatively low number of partners 
during the six months preceding the infection and, although he referred a sporadic use of 
condom, screening for other STDs was negative, except anal warts. Some rare cases of LGV 
in HIV-negative patients who claim a few sexual contacts are reported in literature [53].  
Finally, the clinical history of patient n° 2 should be underlined. In fact, he reported a 
clinical and laboratory healing after treatment with doxycycline, but after about 9 months he 
came back to our Clinic because of a recurrence of rectal symptoms and a new diagnosis of 
LGV proctitis was made. He admitted a new unprotected anal intercourse with one of the 
previous partners who, although informed of the disease, chose not to undergo medical 
check-up and not to take the antibiotic treatment. This behavior underlines the tendency to 
underestimate the risk of acquiring STDs and their possible complications in some groups, 
as HIV-positive MSM.  
 
Three of our patients (60%) are HIV-positive. The HIV infection has been identified as the 
strongest risk factor for anorectal LGV [66] and percentage of co-infection ranges from 67% 
to 100% across the reports [68]. MSM have not been confirmed to be a reservoir of LGV 
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and the high rate of HIV co-infection probably reflects the confounding effect of HIV as a 
surrogate marker of high risk behavior. Nevertheless, a potential effect of HIV infection, 
increasing the susceptibility to infection or facilitating the expression of the disease, cannot 
be ruled out. Since the introduction of highly active anti-retroviral therapy, an increase of 
unprotected sexual practices has been observed worldwide among both HIV -positive and 
HIV-negative MSM; this fact could have contributed to the spread of LGV among MSM 
[67]. In the recent outbreak, the majority of patients were HIV-positive with preserved 
CD4+ cells count, as it is for our patients. Clinical features, answer to treatment and 
outcome of LGV appear to be similar regardless of concomitant HAART, of the count of 
CD4+ or of the viral load [59,66] and therapy with doxycycline for 21 days seems to be 
equally effective both in HIV-negative and -positive patients [37].  
On the other hand, the ulcerative and inflammatory nature of LGV could enhance 
transmission and acquisition of HIV and other STDs; in fact, also the presence of a non-
ulcerative infection may facilitate the infection by HIV through an increase in local 
inflammatory cells, which are the target of this virus [104]. Four of our patients (80%) have 
a positive serology for syphilis, 2 of them diagnosed as early latent syphilis. The association 
between HIV and syphilis has been described previously in several works [105-108]; it may 
be supposed that HIV, syphilis and LGV essentially share common risk behaviors. 
On this topic, we should remember two important concepts that may explain the low use of 
condoms by HIV positive subjects and the increased incidence of STDs and risky sexual 
behavior among MSM since the late Nineties. Firstly, the risk of infection depends upon the 
kind of microorganism and sexual practice: for example, unprotected oral sex is associated 
with a low risk of transmission of HIV and a relatively high risk of transmission of other 
STDs. Secondly, often MSM choose sero-adaptive behaviors so as to reduce the risk of 
transmission of HIV during unprotected anal intercourse. These behaviors tend to reduce the 
transmission of HIV without changing the incidence of other STD; in this regard, we define 
serosorting the selection of partners with the same HIV status and seropositioning the 
behavior for which during anal intercourse the HIV-positive partner is always receptive 
[109,110]. The problem of the increase incidence of other SDTs in HIV-positive MSM is 
very current; some recent studies observed a significant reduction in STD incidence after 
implementing routine STD testing together with a brief risk-reduction counseling from 
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medical providers, offering specific knowledge about non-HIV STDs and their possible 
complications [111]. 
 
In the literature, LGV proctitis is symptomatic in the majority of cases, with percentage 
ranges from 80% to 100% in the different reports; it occurs  in more than 90% of cases with 
a moderate or severe ulcerative proctitis or proctocolitis [67], unlike proctitis caused by C. 
trachomatis non-L that in many cases runs silent [81]. The most reported symptoms are 
rectal pain, anal discharge and rectal bleeding, while functional symptoms are more rarely 
described.  
All our 5 patients were symptomatic and the clinical presentation was similar to those of 
other reports, except for anal/perianal ulceration and functional symptoms (constipation, 
tenesmus), both present in 4 of our patients. Anorectal ulceration are rarely reported in 
literature (4-57% of cases), probably because of their transient nature or of a unique rectal 
location, easily being unnoticed during a visit of the external genitalia. In fact, in a Dutch 
study of 2004, several patients whit LGV underwent sigmoidoscopy that revealed ulcers of 
the rectal ampoule in all of them [112]. Nevertheless, LGV proctitis follows direct infection 
of the rectal mucosa and an ulcerative transient lesion, usually simultaneous to other 
symptoms, may be present, but no clear distinction between "primary" or "secondary" 
proctitis is possible [67,45]. Constipation and tenesmus, probably due to transmural and 
perirectal inflammation and edema associated with the disease, are described in the 
literature as less frequent but more specific than LGV proctitis, compared to other infective 
rectal diseases [73]. 
Inguinal node enlargement are reported in a low number of cases in the literature, with 
percentages ranges from 13% [33,59] to 24% [66] and 43% [34]; 2 of our patients present 
unilateral inguinal lymphadenopathy. This symptom may be linked to the location of the site 
of infection on perianal skin. 
All our LGV cases have anorectal localization and are substantially similar to the cases of 
the literature. Although patients reported passive and active anal intercourse, an urethral 
infection with C. trachomatis serovar L has not been identified. This is in line with the 
general overview reported internationally and emphasizes the problems encountered to 
identify the reservoir of infection and the actual mode of transmission among MSM. It has 
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been hypothesized that the transmission of rectal LGV may be related to other sexual 
activities, such as “fisting” or using sex toys [56,112]. 
 
The scientific literature of the last decades is rich in case reports of LGV proctitis initially 
misdiagnosed with other disease, especially inflammatory bowel disease, since endoscopic 
appearance of the rectal mucosa and sometimes also histological examination show 
common characteristics between the two disease [82,113]. In some cases, the use of 
instrumental tests as endoscopy may delay diagnosis by providing not specific information.  
In our work, patients n° 4 and 5, who underwent endoscopic examination, suffered from the 
biggest delay in diagnosis since endoscopic examination did not lead to the right hypothesis 
and delayed other investigations. The importance of considering the disturbances reported 
by patients, rather than the conclusions drawn exclusively from the results of instrumental 
tests, must be emphasized. 
Differential diagnosis with other STDs must be also remembered: syphilis, perianal herpes 
simplex, C. trachomatis non-L and N. gonorrhoeae proctitis can provide a clinical picture 
very similar to LGV proctitis and should be excluded by laboratory tests [83].  
 
All 5 patients were treated with doxycycline 100 mg twice a day for 21 days, with complete 
resolution of clinical symptoms by the end of treatment, regardless of their HIV status 
[83,114]. Test of cure for rectal C. trachomatis after 3 months did not show any persistence 
of Chlamydia serovar-L DNA in any patient. Patient n°2, who reported a new LGV proctitis 
9 months after the first, was treated again with doxycycline with resolution of clinical 
symptoms. 
 
LGV proctitis is usually associated with significantly higher titre of IgA and IgG antibodies 
in comparison with C. trachomatis non-L infection, probably because of more invasive 
chronic inflammation of the tissue; in fact, LGV serovars are able to leave the host cell at 
the basolateral surface to infect cells under the epithelial layer up to reach the connective 
and lymphatic tissues, in contrast to serovars non-L that remain confined to the epithelium. 
Despite this, IgA and IgG serological titres alone do not allow a certain diagnosis of LGV; 
in case of high titre associated to a positive rectal swab for C. trachomatis in a symptomatic 
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patient diagnosis of LGV is defined probable, while serological high titre in a symptomatic 
patient, without identification of Chlamydia, makes the diagnosis only possible 
[80,115,116]. On the other hand, a low antibody titre does not exclude LGV infection in a 
symptomatic patient. 
In conclusion, although serology is often positive in LGV cases, it is not a suitable method 
for screening and diagnosis, if biovar L specific NAAT is available [116]. All our patients 
present a positivity for IgA and IgG serology with different values which range from titres 
just above the cut-off index to high titres. This variability does not seem to be correlated to 
the HIV state or to the diagnostic delay.  
IgA and IgG antibodies are not really useful even in follow up after treatment, at least 
during the first year. Although IgA reactivity tends to decline after the acute infection, it 
usually does not fall under the cut-off value; the decrease of the IgG titer is usually still 
slower over time. Consequently, IgA and IgG antibodies are not suitable to differentiate past 
effectively treated infection from successive re-infections [117]. This trend of antibodies 
titres is confirmed in our patients; in fact, at the control visit after 3 months, IgA slightly 
decreased in all patients but they are still positive according to our laboratory cut-off and 
IgG are stable or slightly increased. 
 
A certain diagnosis of LGV must be supported by identification of C. trachomatis biovar L. 
In a comparative study between the cell culture and NAATs (nucleic acid amplification 
testing) for diagnosis of infections by C. trachomatis was found that the NAATs are 
significantly more sensitive than culture and they can be considered the new "gold standard" 
for laboratory diagnosis of Chlamydia, both for genital and non-genital infections [118]. In 
particular, the use of Real-Time PCR for diagnosis of infection with C. trachomatis from 
rectal swabs increases up to 100% the possibility of identifying the infection compared to 
culture method [119].  
The major defect of the Real-Time PCR used in our work regards the possibility of a genetic 
mutation of C. trachomatis that could render ineffective its ability in identifying and 
therefore amplifying the DNA of the microorganism. This potential situation was widely 
described in the literature in 2006, when a new variant of C. trachomatis serotype belonging 
to E, with a 377-bp deletion in the cryptic plasmid, was described in Sweden, where a high 
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percentage (10-65%) of infected patients were reported; nowadays there is currently no 
evidence that the variant has spread widely throughout Europe. This new variant cannot be 
detected by amplification of genomic segment deleted, but can be detected by amplification, 
for example, of the chromosomal gene omp1. 
All patients positive for rectal C. trachomatis with Real-Time PCR, have been submitted to 
a Home-made PCR targeting omp1 and subsequently to RFLP. Home-made PCR is well 
described in the literature as a quite rapid, economical and extremely reliable technique 
[101,102]. PCR and RFLP are still abundantly used, especially for the evaluation of samples 
from patients with LGV [119,120]. The main defects of this method are the inability to 
detect punctiform  mutations in the genoma of the microorganism and to identify the sexual 
network to which a certain serotype belongs. However, at least the latter restriction does not 
invalidate the results of our study because sexual networks assessment is outside our 
purposes. 
 
The results of our work do not provide sufficient evidence to recommend routine screening 
by anorectal samples for all MSM but, in line with the European recommendations, they 
confirm, the indication to perform the PCR diagnostic test on rectal swabs and the 
serotyping, in presence of ulcerative proctitis in MSM or in sexual contacts of subjects 
affected by LGV [56,83]. However, even considering the limited number of patients 
examined in our study, the strong association found between LGV and HIV infection 
suggests that screening for LGV may be recommended in all HIV-positive MSM, as already 
proposed in other studies [33]. 
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Conclusions. 
Since 2003, a new outbreak of LGV, mainly with rectal localization, has been spreading 
among MSM in Western Europe, the United States and Australia. LGV proctitis typically 
presents as anorectal syndrome caused by C. trachomatis serovar L2 in most of the cases; 
the main risk factors are HIV positivity and high risk sexual behavior. Well definite data 
about its prevalence are not available; LGV is not subject to mandatory reporting in most of 
the countries and epidemiological surveillance is active only in some countries and it often 
provides data about high-risk population only. Moreover, a certain diagnosis is based on a 
diagnostic test which is not available in every laboratory. 
This disease is certainly present also among the Italian population, but its true prevalence is 
unknown. To our knowledge, less than 20 cases of LGV proctitis have been published in 
Italy until today [121,122,123]; the new outbreak of LGV proctitis is still little known 
among the medical staff who  does not deal routinely with STDs. 
With the present study, we identified and treated 6 cases of LGV proctitis in 5 patients. 
Epidemiological and clinical data and risk factors are broadly in line with the international 
literature. 
With our work, we aim at emphasizing the importance of remember the existence of LGV 
proctitis, especially when we deal with MSM patients complaining of an anorectal 
syndrome; moreover we are interested in reaffirming the importance of asking and 
considering information about the patient’s sexual behavior and the need to address the 
patient to a Center able to make a laboratory diagnosis of certainty with C. trachomatis 
NAATs and serovar typing. 
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